Current projects

The Biotherapy-Bioproduction Integrator is involved in four projects resulting from the call for projects “Biomedicine: improving yields and controlling production costs” and the call for expressions of interest “New biotherapies and production tools”.

The Grand Défi Biomédicaments PC aims to support the establishment of consortia of private and public players who will work on the development of new sensors and their integration into bioproduction systems as well as on the development of the robotisation of bioproduction processes. The objective is to offer manufacturers in the drug industry autonomous and mobile modules to increase the safety, security, yields, robustness and quality of the processes implemented for the production of biomedicines.

The purpose of the AMI was to feed the construction of the acceleration strategy, to identify on the French territory the economic actors concerned and to collect their proposals for projects ready to be financed quickly, or prospective projects likely to be supported within the framework of future calls for projects of the PIA or other devices. These projects have enabled the State to have the most exhaustive vision possible of the initiatives and investment potential in innovation and industrial production, in order to configure its future national support schemes for industry for the next five years.

(source : Investir l’avenir | Biomédicament : annonce des premiers lauréats de l’appel à manifestation d’intérêt (AMI) et de l’appel à projets (AAP) « Grand defi biomédicament » | Gouvernement.fr)

ACCESS

2022-2024

To optimise Mesenchymal Stem Cell (MSC) production through the development of an on-line clinical grade production control system.

Funding: BPI Grand Défi Biomédicaments project call “Improving yields and controlling costs”, “On-line control” axis.

Partners: INDATECH (leader), Ondalys, Cybernano, StemInov, Ypso-Facto, MTInov (LRGP-CNRS/UL and UTCT-CHRU de Nancy).

For more information

IT’SME

2022-2023

To develop a continuous flow biomedical purification tool of reduced size and very low cost of use, suitable for implementation in a modular factory.

Funding: BPI Grand Défi Biomédicaments project call “Improving yields and controlling costs”, “Modular factory” axis.

Partners: IPSOMEL INNOVATION (leader), INSERM – CRCM, LRGP-CNRS/UL, MTInov (LRGP-CNRS/UL).

For more information

SELPHi

2021-2023

To develop and industrialise a new generation of sensors based on holographic imaging via real-time monitoring of cell states, without labelling the cells, at the heart of bio-reactors.

Funding: BPI Grand Défi Biomédicaments project call “Improving yields and controlling costs”, “On-line control” axis.

Partners: IPRASENSE (leader), Sanofi Aventis R&D and Sanofi Pasteur, Servier LSI, CEA Leti, MTInov (LRGP-CNRS/UL and UTCT-CHRU de Nancy).

For more information

SEQRET

2022-2024

To develop an on-line quality control system based on real-time analysis of the secretome of mesenchymal stem cells (MSCs) in production.

Funding: BPI call for expressions of interest “Biotherapies and bioproduction of innovative therapies”.

Partners: Kimialys (lead partner), PhaseLab, MTInov (LRGP-CNRS/UL and UTCT-CHRU de Nancy).

For more information


Other team projects

At least one of the MTInov-LRGP and MTInov-CHRU teams are also collaborating through the following projects.

Bioproduction


 

Cellular therapies


 

OPTI-STEM

2022-2024

Optimisation of MSC production to democratise access and allow diversification of the therapeutic applications of this type of cell and their derivatives.

Funding: BPI call for expressions of interest “Biotherapies and bioproduction of innovative therapies”.

Partners: Cell-Easy (leader), Roquette, RESTORE, TOXALIM, LAAS, LRGP.

TRACE

2018-2024

Production of anti-viral T cells for the treatment of post-transplant infections.

Funding: European Commission, Horizon2020 programme.

Partners: LMU (lead partner), OPBG, LUMC, CHRU-UTCT, ICM, UZG, MILTENY, ORION.

For more information

CLIMBIN

2022-2023

Development of an innovative analytical process control solution to address the issue of optimisation and automation of upstream and downstream process cell culture systems.

Funding: appel à manifestation d’intérêt BPI « Biothérapies et bioproduction de thérapies innovantes ».

Parterns: NMNS-Université de Tours (chef de file), Bio3-IMT, Ondalys, INDATECH, Servier, LRGP.

CHOC-MSC

2021-2023

Production of umbilical cord MSC in the indication of septic shock.

Funding: PHRC interrégional.

Parterns: CHRU-UTCT.

For more information

MSC-COVID

2021-2022

Intensification of umbilical cord mesenchymal stem cell (MSC) production in the indication of acute respiratory distress syndrome secondary to COVID19.

Funding: ANR RA-COVID (wave 7).

Partners: CHRU-UTCT, IMoPA, LRGP.

For more information

COVIBANK

Upcoming start-up (approvals obtained)

Development of anti-SAR-CoV-2 T lymphocytes (CTL-CoViD19) for patients with acute respiratory distress syndrome with persistent lymphopenia.

Partners: CHRU-UTCT.

Project to develop CAR T cells from a defined population such as anti-viral CTLs (CAR-CTL).

Partners: CHRU-UTCT, University of North Carolina.